Abstract:

Polycystic Ovarian Syndrome also called Stein-Leventhal Syndrome or chronic oligoanoSvulation is a condition related to hormonal imbalance that can cause menstrual disorders like oligomenorrhea or amenorrhea, infertility, hirsutism, obesity, suffering from prompt increase in weight or having trouble in losing weight and other symptoms in type two diabetes, oily skin, and acne. Most of the cases of PCOS are reported in 20s and 30s with complain of difficulty in becoming pregnant. According to the study, frequency of PCOS in the infertility clinics in Pakistan was 17.6%. In this study Fenugreek (Trigonellafoenum-graecum) was investigated to treat PCOD. The plant was also subjected to different physico-chemical and nutraceutical estimations. The present study is single blind randomized controlled trial in 90 premenopausal women diagnosed with PCOS using fenugreek seed powder, over a period of 90 consecutive days. During the course of study, the subjects were counseled about diet and exercise and were regularly monitored for any associated side effects related to the administration of fenugreek seed powder. Vital clinical estimations in the human subjects were carried out at the start of study and by the end of trail i.e. at day 90. Clinical estimations involved evaluation of BMI, FSH, LH, ovarian size, menstrual regularity and FBG. Overall results revealed that the prolong administration of raw fenugreek seeds in women having PCOS was particularly found effective. Intake of fenugreek seeds for three months had positive effect on regularity of menstrual cycle, maturation of eggs, reducing ovarian volume and infertility.

Keywords: Polycystic Ovaries, Fenugreek, Infertility, Ovarian Size, Menstrual irregularities.

References:

[1].  Legge. J., E.F Ambassador (2017). Polycystic ovarian syndrome (pcos) – a guide 2017. https://ecofemme.org/polycystic-ovarian-syndrome-pcos-a-guide-2017/.

[2].  Hussein, B., & Alalaf, S. (2013). Prevalence and characteristics of polycystic ovarian syndrome in a sample of infertile Kurdish women attending IVF infertility center in maternity teaching hospital of Erbil City. Open Journal of Obstetrics and Gynecology, 3(07), 577.

[3].  Mullaicharam, A. R., Deori, G., & Maheswari, R. U. (2013). Medicinal values of fenugreek—A review. Res. J. Pharm. Biol. Chem. Sci, 4, 1304-1313.

[4].  Moradi, N., &Moradi, K. (2013). Physiological and pharmaceutical effects of fenugreek (Trigonellafoenum-graecum L.) as a multipurpose and valuable medicinal plant. Global Journal of Medicinal Plant Research, 1(2), 199-206.

[5].  Beretta, G., Granata, P., Ferrero, M., Orioli, M., & Facino, R. M. (2005). Standardization of antioxidant properties of honey by a combination of spectrophotometric/fluorimetric assays and chemometrics. Analytica Chimica Acta, 533(2), 185-191.

[6].  AOAC.1990. Official Method of Analysis.15^th Ed., Association of Official Analytical Chemist. Arlington, VA.USA.

[7].  AOAC. 2000. Official method of Analysis.17^th Ed., Association of Official Analytical Chemist. Gaithersburg, MD.USA.

[8].  AOAC. 2005. Official method of Analysis.18^th Ed., Association of Official Analytical Chemist. Gaithersburg, MD.USA.

[9].  Steel, R. G. D., Torrie, J. H., & Dickey, D. A. (1997). Principles and procedures of statistics: a biometrical approach., 3rd edn (McGraw-Hill: New York).

[10]. Cresswell, J., Fraser, R. B., Bruce, C., Egger, P., Phillips, D., & Barker, D. J. (2003). Relationship between polycystic ovaries, body mass index and insulin resistance. Acta obstetrician et gynecologica Scandinavica, 82(1), 61-64.

[11]. Bashtian, M. H., Emami, S. A., Mousavifar, N., Esmaily, H. A., Mahmoudi, M., & Poor, A. H. M. (2013). Evaluation of fenugreek (Trigonellafoenum-graceum L.), effects seeds extract on insulin resistance in women with polycystic ovarian syndrome. Iranian Journal of Pharmaceutical Research: IJPR, 12(2), 475.

[12]. Swaroop, A., Jaipuriar, A. S., Gupta, S. K., Bagchi, M., Kumar, P., Preuss, H. G., &Bagchi, D. (2015). Efficacy of a novel fenugreek seed extract (Trigonellafoenum-graecum, FurocystTM) in polycystic ovary syndrome (PCOS). International Journal of Medical Sciences, 12(10), 825.

[13]. Pavlik, E. J., DePriest, P. D., Gallion, H. H., Ueland, F. R., Reedy, M. B., Kryscio, R. J., & van Nagell Jr, J. R. (2000). Ovarian volume related to age. Gynecologic Oncology, 77(3), 410-412.

[14]. Van Hooff, M. H., Voorhorst, F. J., Kaptein, M. B., Hirasing, R. A., Koppenaal, C., & Schoemaker, J. (2000). Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertility and Sterility, 74(1), 49-58.

[15]. Diamanti-Kandarakis, E., & Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews, 33(6), 981-1030.

[16]. Dunaif, A., & Book, C. B. (1997). Insulin resistance in the polycystic ovary syndrome. In Clinical Research in Diabetes and Obesity (pp. 249-274).Humana Press, Totowa, NJ.

[17]. Dunaif, A. (2008). Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome reappraisal. Nature Reviews Endocrinology, 4(5),272.

[18]. Ovalle, F., & Azziz, R. (2002). Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertility and Sterility, 77(6), 1095-1105.